MannKind | MNKD - Выручка от реализации





Продажи Изменить Дата
Adma Biologics USD 114.5M 24.66M 2026-03
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Eli Lilly USD 19.8B 500M 2026-03
Halozyme Therapeutics USD 377M 74.76M 2026-03
Insmed USD 305.96M 42.16M 2026-03
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
MacroGenics USD 20.8M 20.43M 2026-03
MannKind USD 90.2M 21.76M 2026-03
Merck USD 16.29B 110M 2026-03
Minerva Neurosciences USD 0 0 2024-09
Novavax USD 147.14M 76.69M 2025-12
Novo Nordisk DKK 12.53B 2.44B 2025-12
Pfizer USD 14.5B 3.08B 2026-03
Sanofi EUR 11.24B 60M 2026-03
Xencor USD 4.51M 23.73M 2026-03